Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment
Hemasphere
.
2022 Jul 4;6(7):e749.
doi: 10.1097/HS9.0000000000000749.
eCollection 2022 Jul.
Authors
Esther E E Drees
1
2
,
Yvonne W S Jauw
2
3
,
Erik van Dijk
1
2
,
Sven Borchmann
4
,
Sandra A W M Verkuijlen
1
2
,
Phylicia Stathi
1
2
,
Nils J Groenewegen
1
2
5
,
Nathalie J Hijmering
1
2
,
Daniella R A I Berry
1
2
,
Eric J Meershoek
6
,
Danielle Hoogmoed
6
,
Anne Kwakman
1
2
,
Tessa J Molenaar
1
2
,
Dirk M Pegtel
1
2
,
Bauke Ylstra
1
2
,
Daphne de Jong
1
2
,
Josée M Zijlstra
2
3
,
Margaretha G M Roemer
1
2
Affiliations
1
Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
2
Program Imaging and Biomarkers, Cancer Center Amsterdam, The Netherlands.
3
Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
4
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Germany.
5
ExBiome B. V., Amsterdam, The Netherlands.
6
Leica Biosystems/Kreatech Diagnostics B.V., Amsterdam, The Netherlands.
PMID:
35813096
PMCID:
PMC9257296
DOI:
10.1097/HS9.0000000000000749
No abstract available